Z
ZVRA
Zevra Therapeutics Inc
10.17
+0.14+1.40%Opening10:30 05/26 EDT
OPEN/PREV CLOSE10.15/10.03
TODAY RANGE10.07-10.27
VOL441.45K
MARKET CAP601.20M
52 WEEK RANGE7.16-13.16
AVG VOL (3M)1.27M
% TURNOVER0.75%
TURNOVER--
P/E (TTM)5.02
% RANGE1.99%
EPS(TTM)2.027
P/E(FORWARD)10.48
P/B2.921
BVPS3.481
DIVIDEND--
P/S5.43
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP583.73M
SHARES OUTSTANDING59.12M
NEXT EARNINGS08/10-08/14
FREE FLOAT57.40M
LOT SIZE1
EX-DATE12/28/2020
News
Press Releases
Financial Reports
Profile
Simply Wall St·05/16 08:00
Did One-Off-Boosted Q1 Profits Just Shift Zevra Therapeutics' (ZVRA) Investment Narrative?
Simply Wall St·05/14 07:51
A Look At Zevra Therapeutics (ZVRA) Valuation After Strong Earnings And SDX Portfolio Sale
TipRanks·05/11 00:22
Zevra Therapeutics Earnings Call Highlights Growth Pivot
Simply Wall St·05/08 18:46
Zevra Therapeutics (ZVRA) Is Up 8.2% After Debt-Free Turnaround And Rare Disease Refocus – What’s Changed
Dow Jones·05/08 13:39
Zevra Therapeutics Is Maintained at Buy by Guggenheim
Benzinga·05/08 13:29
Guggenheim Maintains Buy on Zevra Therapeutics, Raises Price Target to $25
TipRanks·05/08 13:28
Zevra Therapeutics price target raised to $25 from $23 at Guggenheim
TipRanks·05/07 17:36
Zevra Therapeutics (ZVRA) Gets a Buy from Roth MKM
Seeking Alpha·05/07 04:22
Zevra outlines Celiprolol interim analysis trigger at 28 events while expanding MIPLYFFA access
Simply Wall St·05/07 01:42
Assessing Zevra Therapeutics (ZVRA) Valuation After Its First Quarter 2026 Profit Turnaround
Benzinga·05/06 21:03
Earnings Scheduled For May 6, 2026
Same Industry
Name/Symbol
Change%
Price